Trial Profile
A Study Evaluating the Efficacy and Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combination With Ondansetron and Dexamethasone in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 04 Aug 2016
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone; Ondansetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 01 Mar 2013 Actual end date changed from 1 Feb 2010 to 1 Dec 2008 as reported by ClinicalTrials.gov.
- 01 Mar 2013 Actual end date changed from 1 Feb 2010 to 1 Dec 2008 as reported by ClinicalTrials.gov.
- 01 Mar 2013 Actual initiation date changed from 1 Mar 2006 to to 1 Oct 2005 as reported by ClinicalTrials.gov.